Loqtorzi (Toripalimab-Tpzi) Patent Expiration, LOE Window & CMS Spending
Loqtorzi (Toripalimab-Tpzi) by Coherus BioSciences: Biologic BLA (Purple Book Regime), 0 AB generics, $735K 2024 CMS Part D & Medicaid spend, and $8,892 CA SB 17 specialty launch WAC.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Coherus BioSciences |
| FDA Application & Pathway | B761240 (BLA) |
| Exclusivity / Cliff Horizon | Biologic BLA (Purple Book Regime) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | Not listed / N/A |
| Orange Book Patents (*PED Extensions) | 0 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $735K |
| 2024 Medicare Part D Spend | $0 |
| 2024 Medicaid Spend | $735K |
| Reported Wholesale Price Change (CA SB 17) | Specialty launch notice ($8,892 intro WAC) |